This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
TEVA announced on July 27th its intention to withdraw its unsolicited expression of interest to acquire rival Mylan N.V., a leading global pharmaceutical company with a growing portfolio of around 1,400 generic pharmaceuticals and brand medications.
A CRA team provided economic support to Mylan in its antitrust defense in front of the European Commission against the attempted hostile take-over.
After the Court of Justice for the European Union (CJEU) Intel Judgment, one critical open question was how demanding the Court will be in the judicial review...
This report produced by consultants from CRA’s Energy and Competition Practices on behalf of the European Commission provides an assessment of potential...
Mikaël Hervé is a speaker during the session “Competition In The Cloud.” For more information on this event, click here.
CRA is a proud sponsor. Raphaël De Coninck is a speaker. He will discuss ‘Policy Adjustments within the SIEC Framework: What is the Margin of Maneuver?’ as...
